Amgen stock falls after Kissei warns on Tavneos liver risks By Investing.com

Amgen shares fell 2.1% as Tavneos came under intensified regulatory and safety scrutiny, with Japan reporting 20 fatal cases and 22 severe Vanishing Bile Duct Syndrome cases among about 8,503 treated patients. The FDA issued a March 31 warning on severe drug-induced liver injury and, on April 27, 2026, proposed withdrawing U.S. approval over concerns about efficacy and material misstatements in the original application. The EMA also opened a review on January 30, 2026, citing data integrity concerns from the Phase III trial.

Analysis

This is less a one-off product headline and more a credibility shock to AMGN’s post-Horizon asset quality. The market will likely re-rate the acquired portfolio at a discount because the issue is not just safety; it now carries regulatory integrity overhang in the U.S. and Europe, which raises the probability of slower label expansion, channel caution, and broader diligence on the acquired franchise. That makes the near-term damage asymmetric: even if U.S. sales contribution is modest, the multiple compression can spill into how investors underwrite Amgen’s acquisition discipline.

The second-order beneficiary set is the inflammation/autoimmune basket, but not uniformly. Physicians and payers will not abandon the mechanism class overnight; instead, they may shift prescribers toward better-understood alternatives with cleaner hepatotoxicity profiles, which should favor incumbents with larger real-world safety databases and more diversified indications. The bigger winner may be companies with competing rare-disease or vasculitis exposures that are not tied to a single controversial asset, because the event increases the value of regulatory simplicity and post-marketing transparency.

Catalyst risk is front-loaded over days to weeks: another U.S. regulatory action, label restriction, or additional case clustering in Japan could force sell-side estimate cuts and amplify headline risk. Over months, the key question is whether management can ring-fence Tavneos from the rest of the portfolio; if not, the acquisition premium embedded in AMGN’s strategy could compress further. A clean reversal would require a materially different regulatory outcome than the current trajectory, so the burden of proof is now on the company rather than the bears.

The contrarian angle is that the absolute revenue pool is still small relative to AMGN’s core earnings engine, so a full-blown franchise impairment may be over-anticipated in the stock. If the market treats this as a morality play rather than a contained asset-level problem, AMGN could become an attractive long only after the first wave of forced de-risking passes. The better expression today is likely relative value rather than outright conviction long.

Key Decisions for Investors

• Short AMGN tactically for 1-4 weeks into any regulatory follow-through; target a 3-5% downside move on headline extension, with a tight stop if management signals a swift containment plan.
• Pair trade: short AMGN / long LLY or REGN over the next 1-3 months to isolate portfolio-quality and regulatory-trust dispersion; the risk/reward favors the cleaner balance sheets and broader diversification.
• Buy near-dated AMGN puts or put spreads around the next FDA/EMA headline window; upside is capped by the limited direct revenue contribution, while downside can accelerate if analysts start haircutting the acquired asset multiple.
• For longer-term investors, wait for a post-selloff entry only if the stock discounts a low-single-digit drag to FY earnings and management avoids broader acquisition write-down language; otherwise avoid catching the falling knife.